masthead
navBar
shareholderLetter
articles
articles
articles
articles
articles
Page 1 | 2
To read this article in translation:
China
Chinese
France
French
Germany
German
Japan
Japanese
Spain
Spanish
United States of America
English
Cancer remains one of the leading causes of death around the world, with more than 10 million cases diagnosed annually, including over 1.3 million new cases diagnosed each year in the United States alone.
         However, since the mid-twentieth century, when a diagnosis of cancer usually amounted to a death sentence, many cancers have become much more controllable. In the U.S., the National Cancer Institute’s goal of five-year survival in more than 50 percent of cancer cases has been achieved. This is due in no small measure to major advances in radiation oncology—now used either alone or in combination with other therapies to treat up to 60 percent of all cancer patients in the U.S.
         At the center of many of these developments is Varian Medical Systems, formerly known as Varian Associates and now the world’s leading supplier of technology and systems for treating cancer with radiation therapy. Over a period of more than 40 years, Varian has helped to establish and transform radiation oncology through continuous evolution of its medical linear accelerator technology and development of the world’s most comprehensive network of hardware, accessories, and software for radiation therapy. Today, the company stands at the forefront of a major revolution in cancer treatment.
         The goal of radiation therapy is to destroy cancer cells by bombarding them with X rays or electrons. The radiation damages the cancer cells, which later die and are sloughed off by the body. Healthy cells that are exposed to moderate amounts of radiation have the ability to repair themselves and survive. The challenge that radiation oncologists face in every case is how to deliver enough X rays to destroy the cancer without exceeding the level that the surrounding healthy cells can tolerate. Solving this problem simply and effectively has been the driving force behind most of the technological developments that have taken place in radiation therapy over the last several decades.

The Early Years
Initially developed in the early 1900s, radiation therapy was used primarily for relieving pain by shrinking tumors, but not often for cure. The earliest radiotherapy devices used primitive X-ray tubes to generate very weak radiation—not enough to effect cures or to penetrate the body very deeply. Next came cobalt machines that offered higher energy but which delivered relatively slow treatments that lengthened in time as the radioactive source within the machine weakened. The weakened radioactive cobalt source also presented hospitals with a problem of how to dispose of potentially dangerous radioactive waste.

A Technology Is Born
Modern radiation therapy traces its origins back to the invention of the “klystron” by brothers Russell and Sigurd Varian in 1937. The Varian brothers first used their invention in radar systems. However, after World War II, either the klystron or the magnetron, another invention of the time, was used to propel charged particles through a vacuum tunnel, resulting in a device called a linear accelerator or linac. The linac was initially used for research in high energy physics.
         In the early 1950s, Dr. Henry Kaplan, head of Stanford University’s Department of Radiology, met with Edward Ginzton, a Stanford physicist and a Varian co-founder. Kaplan proposed that a linac be specifically designed to generate high energy X rays for the treatment of cancer. The idea was that klystrons would accelerate electrons to near the speed of light. The electrons would then be made to strike a tungsten target causing an emission of X rays of comparable energies. These high-energy X-ray beams would then be used to bombard a cancerous tumor.
         Even amongst the illustrious group of Stanford University researchers, Kaplan and Ginzton were giants, according to Dr. Philip Rubin, Provost Emeritus for Radiation Oncology at the University of Rochester Medical School and a pioneer in the use of X rays against cancer.
         “Henry Kaplan was a charismatic visionary who wanted to have an accelerator in order to treat Hodgkin’s disease,” Dr. Rubin says. “Ginzton was a man who transformed a complex research device into a practical clinical tool. Together, they opened up a whole new universe for radiation therapy.”
         The Kaplan-Ginzton meeting started a chain of research develop-ments that culminated in 1960, when Varian introduced the “Clinac 6,” the first commercial fully rotational radiotherapy linac. The Clinac 6 could generate sharply defined beams of 6 MV X rays in a gantry that could be rotated 360 degrees around a patient. Though limited in production, the Clinac 6 established that linacs could be used to treat cancer, with intrinsic medical advantages over the cobalt irradiators that had been used to treat cancer throughout the 1950s.
         In 1968, Varian introduced the Clinac 4, a machine that deployed “standing wave-guide” technology which, along with other advances, helped to reduce the size, cost, and complexity of a medical linac. For the first time, the linear accelerator technology became economically competitive with cobalt irradiators and was ready to seize center stage. “The arrival of the Clinac 4 marked the birth of modern radiation oncology,” says Dr. Rubin.

 
 
Continued>
1 | 2 | Next >